Future biochemical studies are needed to elucidate whether HTT, ATXN1 and ATXN2 CAG can trigger not only the Htt or ataxin aggregation but also other pathological proteins such as a-syn as well, and this explains their Parkinson’s disease genetic risk. This evidence concerns the gene ATXN2 and Parkinson disease.